Source - LSE Regulatory
RNS Number : 3569P
Advanced Oncotherapy PLC
10 October 2019
 

10 October 2019

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Change of Broker

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that with effect from today Allenby Capital Limited will be the Company's Nominated Adviser and sole Broker.

 

 

Enquiries:

 

Advanced Oncotherapy Plc

Dr. Michael Sinclair, Executive Chairman

Nicolas Serandour, CEO

 

www.avoplc.com

Tel: +44 (0)20 3617 8728

Allenby Capital Limited (Nominated Adviser & Broker)

Nick Athanas / Liz Kirchner / Nicholas Chambers

 

Tel: +44 (0)20 3328 5656

FTI Consulting (Financial PR & IR)

Simon Conway / Rob Winder

 

Tel: +44 (0)20 3727 1000 advancedoncotherapy@fticonsulting.com

 

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
APPBLBDGXGGBGCC
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.